论文部分内容阅读
目的：研究重组人单核细胞趋化蛋白－１ （ｈｕＭＣＰ－１）融合蛋白对人外周血单核细胞体外溶瘤活性的影响。方法：采用乳酸脱氢酶释放法检测ｈｕＭＣＰ－１单独或与细胞因子协同作用下的单核细胞溶瘤活性。结果：１０ μｇ／ｍ ｌ的重组ｈｕＭＣＰ－１可促进人单核细胞对人胃腺癌细胞ＳＧＣ－７９０１ 和人结肠癌细胞Ｈｃｅ－８６９３ 的体外溶瘤活性（Ｐ＜ ０．０１）。１００ Ｕ／ｍ ｌ的ＩＦＮγ与１ μｇ／ｍ ｌ的重组ｈｕＭＣＰ－１ 在增强单核细胞对ＳＧＣ－７９０１ 和Ｈｃｅ－８６９３ 细胞的溶瘤作用方面具有协同作用（Ｐ＜ ０．０５）。１００ Ｕ／ｍ ｌＴＮＦ可分别与０．１ 或１ μｇ／ｍ ｌ重组ｈｕＭＣＰ－１协同增强单核细胞的溶瘤作用（Ｐ＜ ０．０１）。结论：ｈｕＭＣＰ－１单独或与ＴＮＦ、ＩＦＮγ协同作用可增强单核细胞的体外溶瘤活性。
Objective: To study the effect of recombinant human monocyte chemoattractant protein-1 (huMCP-1) fusion protein on the in vitro oncolytic activity of human peripheral blood mononuclear cells. Methods: Lactate dehydrogenase release assay was used to detect monocyte oncolytic activity of huMCP-1 alone or in combination with cytokines. RESULTS: Recombinant huMCP-1 at 10 μg/ml promoted the in vitro oncolytic activity of human monocytes against human gastric adenocarcinoma cells SGC-7901 and human colon cancer cells Hce-8693 (P < 0.01). 100 U/ml of IFNγ and 1 μg/ml of recombinant huMCP-1 had a synergistic effect in enhancing the monocyte’s oncolytic effect on SGC-7901 and Hce-8693 cells (P<0.05). 100 U/ml lTNF could synergistically enhance monocyte oncolysis with 0.1 or 1 μg/ml of recombinant huMCP-1 (P < 0.01). CONCLUSION: The synergistic effects of huMCP-1 alone or in combination with TNF and IFNγ can enhance the in vitro oncolytic activity of monocytes.